Prothena Corporation plc
Prothena Corp plc (Form: 8-K, Received: 06/29/2015 16:10:59)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K  
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2015
_______________________________________________________

PROTHENA CORPORATION PUBLIC LIMITED COMPANY
(Exact Name of Registrant as Specified in its Charter)
_______________________________________________________
 
 
 
 
 
Ireland
 
001-35676
 
98-1111119
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
 
Alexandra House
The Sweepstakes, Ballsbridge
Dublin 4, Ireland
(Address of principal executive offices including Zip Code)
Registrant’s telephone number, including area code: 011-353-1-902-3519
(Former Name or Former Address, if Changed Since Last Report.)  
_______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On June 29, 2015, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) appointed Anders O. Härfstrand, M.D., Ph.D., to serve as a director of the Company, effective immediately.
In connection with his appointment, Dr. Härfstrand was granted an option to acquire 30,000 of the Company’s ordinary shares under the Company’s Amended and Restated 2012 Long Term Incentive Plan, with a per share exercise price equal to the last reported sale price on the Nasdaq Global Select Market of the Company’s ordinary shares on June 29, 2015, the date of grant and the date of Dr. Härfstrand’s appointment to the Board. The option will vest in equal annual installments over three years, subject to Dr. Härfstrand’s continuous service on the Board until each such vesting date.

Consistent with the Company’s new compensation program for its non-employee directors, Dr. Härfstrand will also be eligible to receive the following compensation for his service as a director:

An annual cash retainer in the amount of $50,000 (which will be paid in quarterly installments); and

An annual grant of an option to acquire 15,000 of the Company’s ordinary shares under the Company’s Amended and Restated 2012 Long Term Incentive Plan, with a per share exercise price equal to the last reported sale price on the Nasdaq Global Select Market of the Company’s ordinary shares on the date of grant, which grant will be the day following each annual general meeting of the Company’s shareholders if Dr. Härfstrand is serving on the Board on that date. This option will vest in full on the earlier of the first anniversary of the grant date or the day prior to the next annual general meeting of the Company’s shareholders, subject to Dr. Härfstrand’s continuous service on the Board until such vesting date.

The Company has entered into its standard Deed of Indemnification with Dr. Härfstrand.
A copy of the press release announcing the appointment of Dr. Härfstrand is filed as Exhibit 99.1 to this report.
Item 9.01.
Financial Statements and Exhibits
(d)  Exhibits .
 
 
 
Exhibit No.
 
Description
99.1
 
Press Release dated June 29, 2015.








SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:
June 29, 2015
PROTHENA CORPORATION PLC
 
 
 
 
 
 
 
By:
 
/s/ Tran B. Nguyen
 
 
Name:
 
Tran B. Nguyen
 
 
Title:
 
Chief Financial Officer





Exhibit 99.1
                                                
Prothena Announces Addition of Seasoned Executive to Board of Directors

DUBLIN, Ireland - June 29, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced the appointment of Anders Härfstrand, MD, PhD, to its Board of Directors.

“Anders’ wealth of strategic expertise leading both entrepreneurial and large commercial organizations will serve as a valuable asset as we continue development of our pipeline of potential therapies, and in particular as we move NEOD001 towards commercialization,” said Lars Ekman, MD, PhD, Chairman of Prothena’s Board of Directors. “We welcome Anders to the Board and look forward to his guidance as we continue to advance three clinical-stage programs toward commercialization, to bring new disease-modifying therapeutics to transform patients’ lives.”

Anders Härfstrand, MD, PhD

Dr. Härfstrand was most recently the CEO of BBB Therapeutics BV, a Netherlands company focused on neuro-oncology and neuro-inflammatory products. Prior to his tenure at BBB Therapeutics, he served as President and CEO Europe of Makhteshim Agan Industries Ltd.; President and CEO of Humabs BioMed SA; and CEO of Nitec Pharma AG (now Horizon Pharma), where he guided one product to approval in Europe, successfully merged a company and was instrumental in driving a multimillion dollar out-licensing relationship for multiple products. Previously, Dr. Härfstrand served in roles of increasing responsibility at major pharmaceutical companies in the U.S., Europe and Japan, including Serono, Pfizer and Pharmacia. Dr. Härfstrand has also served in non-executive roles on a number of Supervisory Boards in Europe. During his career, Dr. Härfstrand has had responsibility for the development and commercialization of pharmaceutical brands in numerous global markets. Dr. Härfstrand graduated with a MD degree from Karolinska Institute, in Stockholm, Sweden, in 1983, and earned a PhD in neuropharmacology endocrinology from Karolinska Institute in 1987.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the company's web site at www.prothena.com .

Contact
Investors:  Tran Nguyen, CFO
650-837-8535,  IR@prothena.com
Media:  Angela Bitting
925-202-6211, angela.bitting@prothena.com